Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

46074

Supelco

Betamethasone 17-valerate

VETRANAL®, analytical standard

Synonym(s):

1,4-Pregnadiene-11β,17α,21-triol-9α-fluoro-16β-methyl-3,20-dione 17-valerate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17-valerate, 9α-Fluoro-16β-methylprednisolone 17-valerate, Betnovate

Sign Into View Organizational & Contract Pricing

Select a Size

250 MG
$103.00

$103.00

Available to ship onApril 25, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
250 MG
$103.00

About This Item

Empirical Formula (Hill Notation):
C27H37FO6
CAS Number:
2152-44-5
Molecular Weight:
476.58
Beilstein/REAXYS Number:
4240001
EC Number:
218-439-3
MDL number:
MFCD00867446
UNSPSC Code:
41116107
PubChem Substance ID:
329756595
NACRES:
NA.24

$103.00

Available to ship onApril 25, 2025Details

Request a Bulk Order

grade

analytical standard

Quality Level

200

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

clinical

format

neat

storage temp.

2-8°C

SMILES string

CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO

InChI

1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19?,20?,21-,24-,25-,26-,27-/m0/s1

InChI key

SNHRLVCMMWUAJD-QDHNOTTGSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 2

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCD9152
BCBZ6169

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Diphenhydramine hydrochloride ≥98% (HPLC)

Sigma-Aldrich

D3630

Diphenhydramine hydrochloride

Prakash Adhikari et al.
International journal of pediatric otorhinolaryngology, 75(4), 500-503 (2011-02-05)
This study was carried out with the objective of comparing clinical efficacy of 10% ichthammol glycerine (IG) pack with steroid-antibiotic pack for relieving pain in cases of acute otitis externa. A prospective quasi-randomized clinical trial was completely carried out in
Taner Senyiğit et al.
International journal of pharmaceutics, 403(1-2), 123-129 (2010-11-05)
The aim of this study was to evaluate the suitability of sodium-deoxycholate (Na-DOC) gels containing betamethasone-17-valerate (BMV) for topical application. The gels were characterized for rheological and textural properties. The in vitro flux of BMV from Na-DOC gels across rat
Atsuko Kamo et al.
Journal of dermatological science, 62(2), 91-97 (2011-04-05)
UV-based therapy has anti-pruritic effects in inflammatory skin diseases, such as atopic dermatitis and psoriasis. These anti-pruritic effects may be partly due to inhibition of intraepidermal nerve growth, but they have not been fully characterized. This study was performed to
Christine Bangert et al.
Dermatology (Basel, Switzerland), 222(1), 36-48 (2010-12-15)
Topical pimecrolimus may maintain remissions of atopic dermatitis (AD) by inhibiting subclinical inflammation. To evaluate clinical and cytological effects of pimecrolimus in topical corticosteroid-treated and resolved AD lesions. Patients (n=67) with resolved AD lesions were randomized to 3-week double-blind treatment
L B Jensen et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 79(1), 68-75 (2011-06-15)
Treatment of skin diseases implies application of a drug to skin with an impaired epidermal barrier, which is likely to affect the penetration profile of the drug substance as well as the carrier into the skin. To elucidate this, the
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service